Anthony R. Mato, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-160
3400 Civic Center Blvd
Philadelphia, Pa 19104
Office: 215-615-7361
Fax: 215-615-5888
Education:
BS (Biology)
Cornell University , 1998.
MD (Internal Medicine)
SUNY at Buffalo, School of Medicine, 2002.
MSCE (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Landsburg D, Falkiewicz M, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill B, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy N, Singavi A, Fenske TS, Chavez J, Kaplan J, Behdad A, Petrich A, Bast MA, Vose JM, Olszewski A, Costa C, Lansigan F, Gerson J, Barta SK, Calzada O, Cohen JB, Lue J, Amengual J, Rivera X, Persky D, Peace D, Nathan S, Cssaday R.: Outcomes of double hit lymphoma patients who achieve first complete remission Journal of Clinical Oncology May 5 2017 Notes: Epub ahead of print.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Karbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.: Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi- Center Study of 683 Patients. Annals of Oncology 28(5): 1050-1056, May 1 2017

Catherine Daniel, Anthony R. Mato: BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia. Hematology & Oncology 15(3): 210-218, Mar 2017

Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick DE, Kiselev P, Sharman, JP. : Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: Prospective evaluation on 455 patients treated in the United States BMC Cancer 17(1): 198, Mar 16 2017

Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R, Nabhan C, Schuster SJ.: Comparable outcomes in Chronic Lymphocytic Leukemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-center study. British Journal of Hematology Feb 21 2017 Notes: Epub ahead of print

Schachter LG, Mato AR.: An update on immunotherapies including chimeric antigen receptor T-cells therapy and stem cell transplantation in chronic lymphocytic leukemia. Translational Cancer Research Feb 2017 Notes: Epub ahead of print.

Nabhan C, Mato AR. : Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model. Journal of Clinical Oncology 2017 Notes: Published online before print March 13, 2017

Anthony R Mato, Meghan C Thompson, Chadi Nabhan, Jakub Svoboda, Stephen J Schuster: Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review. Clinical Lymphoma Myeloma and Leukemia 2017

Allison M Winter, Daniel J Landsburg, Anthony R Mato, Krista Isaac, Francisco J Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R Smith, Paolo Caimi, Deepa Jagadeesh, Brian T Hill: A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. BLOOD 2017

Chadi Nabhan, Anthony R Mato: Emerging Strategies in Treating Double Hit Lymphomas. Clinical Lymphoma Myeloma and Leukemia 2017

back to top
Last updated: 08/16/2017
The Trustees of the University of Pennsylvania